NDA 204708 · Galderma Labs Lp
Mirvaso
Brimonidine Tartrate · Topical
Last checked: Nov 19, 2026Latest source record: Jul 27, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Aug 23, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
177
44 Phase 3, 5 recruiting
FAERS reports
4,408
1,945 serious, 191 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 24, 2024.
MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. MIRVASO (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.( 1 )
Mechanism: Brimonidine is a relatively selective alpha-2 adrenergic agonist. Topical application of MIRVASO topical gel may reduce erythema through direct vasoconstriction.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 23, 2013 Original approval · Type 3 - New Dosage Form ReviewSummary ReviewLetter
1 products under this application
- MIRVASO · BRIMONIDINE TARTRATE EQ 0.33% BASE · GEL, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Brimonidine" as an intervention, any sponsor and status, largest first.
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01309204 · 1,184 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension; Vehicle and 2 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297920 · 1,062 participants · Start Mar 2011 · Primary completion Jun 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%Pivotal-lookingCompleted
Alcon ResearchIndustry
NCT01297517 · 1,001 participants · Start Feb 2011 · Primary completion Mar 2012
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide ophthalmic suspension, 1% and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPivotal-lookingCompleted
Alcon ResearchIndustry
NCT01310777 · 771 participants · Start May 2011 · Primary completion Jan 2013
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension; Brinzolamide 1% ophthalmic suspension and 1 more · For: Open-Angle Glaucoma; Ocular Hypertension
- Evaluation of Safety and Efficacy of PDP-716Pivotal-lookingCompleted
Sun Pharma Advanced Research Company LimitedIndustry
NCT03450629 · 682 participants · Start Sep 13, 2018 · Primary completion Dec 1, 2020
Drug: Brimonidine Tartrate Ophthalmic Suspension; Brimonidine Tartrate Ophthalmic Solution · For: Open Angle Glaucoma; Ocular Hypertension
Sites: Chandler, Arizona; Prescott, Arizona; Sun City, Arizona · 47 sites in all
- Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaPivotal-lookingCompleted
Visus TherapeuticsAcademic, hospital or other
NCT05135286 · 629 participants · Start Mar 15, 2022 · Primary completion Mar 13, 2025
Drug: BRIMOCHOL™ PF; Carbachol PF and 1 more · For: Presbyopia
Sites: Chandler, Arizona; Phoenix, Arizona; Sun City, Arizona · 42 sites in all
- Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension PatientsPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00651612 · 604 participants · Start Nov 2005 · Primary completion Jan 2007
Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution; Concurrent brimonidine 0.2% and 0.5% timolol · For: Glaucoma; Ocular Hypertension
Sites: Newport Beach, California
- Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00332436 · 586 participants · Start Dec 1999 · Primary completion Nov 2001
Drug: brimonidine/timolol fixed combination · For: Ocular Hypertension
Sites: Louisville, Kentucky
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- erythema578
- drug ineffective297
- eye pain289
- flushing285
- condition aggravated276
- product use issue256
- eye irritation227
- headache196
- fatigue194
- skin burning sensation179
- rosacea174
- vision blurred173
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 39 |
| 2006 | 36 |
| 2007 | 53 |
| 2008 | 37 |
| 2009 | 45 |
| 2010 | 55 |
| 2011 | 81 |
| 2012 | 77 |
| 2013 | 101 |
| 2014 | 334 |
| 2015 | 346 |
| 2016 | 234 |
| 2017 | 219 |
| 2018 | 200 |
| 2019 | 196 |
| 2020 | 301 |
| 2021 | 242 |
| 2022 | 259 |
| 2023 | 301 |
| 2024 | 333 |
| 2025 | 381 |
| 2026 | 510 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mirvaso (Brimonidine Tartrate)
2024 spending
$395K
Beneficiaries
264
586 claims
Per beneficiary
$1,497
$20.58 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,017,667 |
| 2021 | $2,070,539 |
| 2022 | $2,219,876 |
| 2023 | $898,665 |
| 2024 | $395,172 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Post-acne erythema treatment: A systematic review of the literature.
Kalantari Y, Dadkhahfar S, Etesami I · J Cosmet Dermatol 2022 · Systematic Review
- Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, et al. · Ophthalmology 2016 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.
van Zuuren EJ, Fedorowicz Z, Tan J, et al. · Br J Dermatol 2019 · Systematic Review
- Interventions for rosacea.
van Zuuren EJ, Fedorowicz Z, Carter B, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Neuroprotection for treatment of glaucoma in adults.
Sena DF, Lindsley K · Cochrane Database Syst Rev 2017 · Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.